These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 8637685)
1. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Tamesis RR; Rodriguez A; Christen WG; Akova YA; Messmer E; Foster CS Ophthalmology; 1996 May; 103(5):768-75. PubMed ID: 8637685 [TBL] [Abstract][Full Text] [Related]
2. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Lane L; Tamesis R; Rodriguez A; Christen W; Akova YA; Messmer E; Pedroza-Seres M; Barney N; Foster CS Ophthalmology; 1995 Oct; 102(10):1530-5. PubMed ID: 9097802 [TBL] [Abstract][Full Text] [Related]
3. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Miserocchi E; Baltatzis S; Roque MR; Ahmed AR; Foster CS Ophthalmology; 2002 Jan; 109(1):111-8. PubMed ID: 11772589 [TBL] [Abstract][Full Text] [Related]
7. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Jabs DA; Rosenbaum JT; Foster CS; Holland GN; Jaffe GJ; Louie JS; Nussenblatt RB; Stiehm ER; Tessler H; Van Gelder RN; Whitcup SM; Yocum D Am J Ophthalmol; 2000 Oct; 130(4):492-513. PubMed ID: 11024423 [TBL] [Abstract][Full Text] [Related]
8. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Thorne JE; Woreta FA; Jabs DA; Anhalt GJ Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554 [TBL] [Abstract][Full Text] [Related]
9. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Baker KB; Spurrier NJ; Watkins AS; Smith JR; Rosenbaum JT Br J Ophthalmol; 2006 Dec; 90(12):1481-5. PubMed ID: 16914474 [TBL] [Abstract][Full Text] [Related]
10. Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus. Neumann R; Foster CS Retina; 1995; 15(3):201-12. PubMed ID: 7569347 [TBL] [Abstract][Full Text] [Related]
11. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Durrani K; Papaliodis GN; Foster CS Ophthalmology; 2004 May; 111(5):960-5. PubMed ID: 15121375 [TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases. Kanzler S; Gerken G; Dienes HP; Meyer zum Büschenfelde KH; Lohse AW Z Gastroenterol; 1997 Jul; 35(7):571-8. PubMed ID: 9273991 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and prognosis of myasthenia gravis in older people. Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive therapy in ocular cicatricial pemphigoid. Mondino BJ; Brown SI Am J Ophthalmol; 1983 Oct; 96(4):453-9. PubMed ID: 6353928 [TBL] [Abstract][Full Text] [Related]